These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 7603014)

  • 21. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
    Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
    Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
    Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
    Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
    Kuo CC; Hsieh HP; Pan WY; Chen CP; Liou JP; Lee SJ; Chang YL; Chen LT; Chen CT; Chang JY
    Cancer Res; 2004 Jul; 64(13):4621-8. PubMed ID: 15231674
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
    Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis.
    Gallahan D; Jhappan C; Robinson G; Hennighausen L; Sharp R; Kordon E; Callahan R; Merlino G; Smith GH
    Cancer Res; 1996 Apr; 56(8):1775-85. PubMed ID: 8620493
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents.
    Nicoletti MI; Valoti G; Giannakakou P; Zhan Z; Kim JH; Lucchini V; Landoni F; Mayo JG; Giavazzi R; Fojo T
    Clin Cancer Res; 2001 Sep; 7(9):2912-22. PubMed ID: 11555610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
    Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
    Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
    Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth inhibition of a human ovarian tumor by a novel paclitaxel derivative in SCID mice.
    Ahmad I; Masters GR; Schupsky JJ; Nguyen J; Ali S; Janoff AS; Mayhew E
    Oncol Res; 1999; 11(6):273-80. PubMed ID: 10691029
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Double blockade of cell cycle at g(1)-s transition and m phase by 3-iodoacetamido benzoyl ethyl ester, a new type of tubulin ligand.
    Jiang JD; Denner L; Ling YH; Li JN; Davis A; Wang Y; Li Y; Roboz J; Wang LG; Perez-Soler R; Marcelli M; Bekesi G; Holland JF
    Cancer Res; 2002 Nov; 62(21):6080-8. PubMed ID: 12414632
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A high-throughput model for screening anti-tumor agents capable of promoting polymerization of tubulin in vitro.
    Hu W; Dong H; Li YZ; Hu XT; Han GJ; Qu YB
    Acta Pharmacol Sin; 2004 Jun; 25(6):775-82. PubMed ID: 15169631
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxol: a review of its preclinical in vivo antitumor activity.
    Rose WC
    Anticancer Drugs; 1992 Aug; 3(4):311-21. PubMed ID: 1358264
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative interaction between mutant p53 and des(1-3)IGF-I accelerates mammary tumorigenesis.
    Hadsell DL; Murphy KL; Bonnette SG; Reece N; Laucirica R; Rosen JM
    Oncogene; 2000 Feb; 19(7):889-98. PubMed ID: 10702797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adenovirus-mediated p53 gene therapy and paclitaxel have synergistic efficacy in models of human head and neck, ovarian, prostate, and breast cancer.
    Nielsen LL; Lipari P; Dell J; Gurnani M; Hajian G
    Clin Cancer Res; 1998 Apr; 4(4):835-46. PubMed ID: 9563876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Are syngeneic mouse tumor models still valuable experimental models in the field of anti-cancer drug discovery?
    Darro F; Decaestecker C; Gaussin JF; Mortier S; Van Ginckel R; Kiss R
    Int J Oncol; 2005 Sep; 27(3):607-16. PubMed ID: 16077908
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of a novel podophyllotoxin derivative (TOP-53) against lung cancer and lung metastatic cancer.
    Utsugi T; Shibata J; Sugimoto Y; Aoyagi K; Wierzba K; Kobunai T; Terada T; Oh-hara T; Tsuruo T; Yamada Y
    Cancer Res; 1996 Jun; 56(12):2809-14. PubMed ID: 8665518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Synthesis and biological evaluation of paclitaxel-thiocolchicine hybrids.
    Danieli B; Giardini A; Lesma G; Passarella D; Silvani A; Appendino G; Noncovich A; Fontana G; Bombardelli E; Sterner O
    Chem Biodivers; 2004 Feb; 1(2):327-45. PubMed ID: 17191851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel Taxol formulation: polyvinylpyrrolidone nanoparticle-encapsulated Taxol for drug delivery in cancer therapy.
    Sharma D; Chelvi TP; Kaur J; Chakravorty K; De TK; Maitra A; Ralhan R
    Oncol Res; 1996; 8(7-8):281-6. PubMed ID: 8938791
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.